In this regard, we recently showed that vemurafenib disrupts mitochondrial dynamics in BRAFV600E-mutated melanoma cells through the inhibition of the MAPK/ERK pathway, decreasing DRP1 activation and increasing MFN1/2 (mitofusin 1/2) and OPA1 (optic atrophy 1) levels, which results in a hyperfused mitochondrial phenotype [20]. This evidence concerns the gene DNM1L and melanoma.